A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma
- PMID: 37067402
- DOI: 10.1002/mc.23549
A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma
Abstract
A splicing factor is as an important upstream regulator of the alternative splicing process. Hence, it is considered to be a therapeutic target for hepatocellular carcinoma (HCC) tissues. In this study, a systems biology-based methodology was used to screen the essential splicing factors precisely and efficiently. A more comprehensive set of alternative splicing events, which were linked to patient survival, was constructed by performing the bivariate Cox regression and receiver operating characteristic (ROC) analyses. Then, the expression data was obtained from The Cancer Genome Altas (TCGA) data set and the three Gene Expression Omnibus (GEO) datasets. It was used to obtain the survival-related splicing factors, which showed a significantly differential expression in the tumor and normal tissues. Using the topological properties of the bipartite graph association network of the alternative splicing events and the splicing factors, we identified the five key splicing factors. Among them, four factors were found to play a prominent role in the development of HCC. The remaining factor was Survival Motor Neuron Domain Containing 1(SMNDC1), which showed a positive correlation with the immune cell infiltration, the biomarkers of immune cells, and the immune checkpoint genes. By performing quantitative real-time polymerase chain reaction analyses, we proved that SMNDC1 was overexpressed in tumor cells. Following the knockdown of its expression, the proliferation and the migration of HCC cells could be suppressed. These results confirmed that the screening method of this study was reliable and accurate. It provided new insights into the mechanism through which splicing factors elicit tumor development.
Keywords: alternative splicing events; bipartite graph association network; hepatocellular carcinoma; splicing factor.
© 2023 Wiley Periodicals LLC.
References
REFERENCES
-
- Chen F. Molecular signature of hepatocellular carcinoma, hope or hype in prognosis and therapy. Sem Cancer Biol. 2011;21(1):1-3.
-
- Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
-
- Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harbor Perspect Med. 2015;5(9):a021535.
-
- Luo C, Cheng Y, Liu Y, et al. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development. Cancer Res. 2017;77(5):1168-1178.
-
- Yuan J, Liu X, Wang T, et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nature Cell Biol. 2017;19(7):820-832.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
Grants and funding
- 32070395/National Natural Science Foundation of China
- 82103055/National Natural Science Foundation of China
- BX20200308/China Post-Doctoral Innovative Talent Support Program
- 212102310175/Key Science and Technology Research Project of Henan Province of China
- GZK1202130/Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
